Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6DK9A)

• Drug Name: PVX-410 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Phase 2	[1]
Triple negative breast cancer	2C60-2C65	Phase 2	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]

• Cross-matching ID: TTD Drug ID: DM6DK9A

Molecule-Related Drug Atlas

Drug(s) Targeting SLAM family member 7 SLAMF7 (CS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Elotuzumab	DMEYHG9	Multiple myeloma	2A83	Approved	[4]
BCMA-CS1 cCAR	DMEPHMR	Multiple myeloma	2A83	Phase 1	[5]
CS1-CAR T Therapy	DMU8OCN	Plasma cell myeloma	2A83.1	Phase 1	[6]
ABBV-838	DMZM0T8	Multiple myeloma	2A83	Phase 1	[7]
MB-104	DMRP4BM	Multiple myeloma	2A83	Phase 1	[8]
UCARTCS1	DM2Y4D7	Multiple myeloma	2A83	Phase 1	[9]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
SLAM family member 7 SLAMF7 (CS1)	TT7ILZ1	SLAF7_HUMAN	Modulator	[4]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] ClinicalTrials.gov (NCT04634747) A Single-Arm, Open-Label, Multi-Center Phase II Study to Evaluate the Combination of PVX-410 + Pembrolizumab + Chemotherapy for Frontline Therapy of Metastatic, PD-L1+ Triple-Negative Breast Cancer (TNBC) in HLA-A2-Positive Patients. U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT01718899) Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma. U.S. National Institutes of Health.
• [4] Market watch: Upcoming catalysts in Q2 2015. Nat Rev Drug Discov. 2015 Apr;14(4):228.
• [5] ClinicalTrials.gov (NCT04156269) BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma. U.S. National Institutes of Health.
• [6] ClinicalTrials.gov (NCT03710421) CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Clinical pipeline report, company report or official report of Mustang Bio.
• [9] ClinicalTrials.gov (NCT04142619) Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01). U.S. National Institutes of Health.